Node Not Found: -- Meetings - The ASCO Post

NCCN 10th Annual Congress on Hematologic Malignancies

NCCN Unveils Graphic Evidence Blocks to Guide Decision-Making

Treatment decision-making for oncologists and their patients may become simpler through the use of graphic NCCN Evidence Blocks™, which were unveiled at the NCCN 10th Annual Congress: Hematologic Mali...


Changing the Outlook for Chronic Lymphocytic Leukemia

Small-molecule inhibitors, especially ibrutinib (Imbruvica) and idelalisib (Zydelig), have greatly changed the outlook for patients with chronic lymphocytic leukemia. William G. Wierda, MD, PhD, Profe...

Hematologic Malignancies

Genomics Now Driving Treatment of Waldenström’s Macroglobulinemia

The treatment of Waldenström’s macroglobulinemia has been greatly impacted by an understanding of its genomics, according to Steven P. Treon, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center ...


Chronic Myelogenous Leukemia: What Drug for Which Patient?

Treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors is “the golden child success story of targeted treatment,” Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research ...

Optimizing the Treatment of HIV-Associated Lymphoma

Non-Hodgkin lymphoma (NHL) associated with human immunodeficiency virus (HIV) infection generally can be treated the same as lymphoma in non–HIV-infected patients, with a few caveats, according to Law...




click me